Literature DB >> 7769192

Two cases from the spectrum of nonalcoholic steatohepatitis.

M Abdelmalek1, J Ludwig, K D Lindor.   

Abstract

Nonalcoholic steatohepatitis is a poorly understood disease that mimics alcoholic liver disease histologically. Its natural history is not well defined, although gradual progression to cirrhosis has been described. Most patients with this condition have been obese, with or without associated diabetes or hyperlipidemia. No known effective treatment exists for nonalcoholic steatohepatitis, although weight loss may have a beneficial effect. We report two cases of nonalcoholic steatohepatitis. One patient with well-established nonalcoholic steatohepatitis had cirrhosis with a complete loss of fat on subsequent liver biopsy despite a gain in weight, simulating cryptogenic cirrhosis. In another patient, the condition improved after use of ursodeoxycholic acid; this agent may be a potential therapeutic agent for the treatment of nonalcoholic steatohepatitis. We believe these two cases represent the spectrum of this condition: on the one end is a progressive liver disease that in some instances may be a cause of cryptogenic cirrhosis; at the other end, a potentially treatable liver condition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769192     DOI: 10.1097/00004836-199503000-00011

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  15 in total

1.  Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.

Authors:  Susumu Itoh; Azuma Kanazuka; Takahide Akimoto
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

Review 2.  Cryptogenic cirrhosis: what are we missing?

Authors:  Stephen Caldwell
Journal:  Curr Gastroenterol Rep       Date:  2010-02

3.  Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis.

Authors:  Waleed M Alazmi; Arie Regev; Enrique G Molina; Eugene R Schiff
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

4.  Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.

Authors:  Jian-Gao Fan; Lan Zhong; Li-Yan Tia; Zheng-Jie Xu; Min-Sheng Li; Guo-Liang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

5.  Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.

Authors:  Jennifer C Price; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien
Journal:  Hepatology       Date:  2017-02-03       Impact factor: 17.425

Review 6.  Mechanisms and significance of liver steatosis in hepatitis C virus infection.

Authors:  Francesco Negro
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

7.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Aynur Unalp; Cynthia E Behling; Joel E Lavine; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

Review 8.  Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.

Authors:  David E Kleiner; Hala R Makhlouf
Journal:  Clin Liver Dis       Date:  2015-12-28       Impact factor: 6.126

Review 9.  Role of liver biopsy in nonalcoholic fatty liver disease.

Authors:  I L Ke Nalbantoglu; Elizabeth M Brunt
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

10.  Steatosis affects chronic hepatitis C progression in a genotype specific way.

Authors:  L Rubbia-Brandt; P Fabris; S Paganin; G Leandro; P-J Male; E Giostra; A Carlotto; L Bozzola; A Smedile; F Negro
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.